Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
Vistagen has completed the last patient visit in the randomized, double-blind, placebo-controlled portion of its Phase 3 PALISADE-4 study for fasedienol, a nasal spray for the acute treatment of social anxiety disorder. Topline results for the randomized portion of the study are expected to be announced in the second quarter of 2026.
Key figures
- Drug Name
- Fasedienol
- Phase Of Trial
- Phase 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.